Aeglea BioTherapeutics Interest Expense 2011-2026 | AGLE

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Aeglea BioTherapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
29.5 M	-20.7 M	-19.1 M	-7 K	-122 K	-5 K	-63 K	-57 K	-42 K	-36 K	-2 K	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
29.5 M	-20.7 M	-974 K

Quarterly Interest Expense Aeglea BioTherapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
40.3 M	-656 K	2.29 M	-	-18.8 M	-610 K	-483 K	-	2.34 M	-8 K	-72 K	-	24 K	5 K	-30 K	-	-24 K	-52 K	-31 K	-	2 K	-19 K	-6 K	-	-12 K	-16 K	-17 K	-	-13 K	-7 K	-17 K	-	-12 K	-12 K	-11 K	-	-9 K	-9 K	-6 K	-	-1 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
40.3 M	-18.8 M	776 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
BioNTech SE BNTX	14.2 M	$ 97.57	2.17 %	$ 27.2 B	Germany
Aligos Therapeutics ALGS	2.2 M	$ 8.49	6.25 %	$ 83.9 M	USA
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.63	-2.42 %	$ 8.73 B	Australia
I-Mab IMAB	722 K	-	-	$ 866 M	China
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Applied Therapeutics APLT	-27 K	-	-	$ 8.42 M	USA
Esperion Therapeutics ESPR	3.49 M	$ 2.15	-0.69 %	$ 447 M	USA
Amphastar Pharmaceuticals AMPH	23 K	$ 20.87	2.45 %	$ 976 M	USA
GT Biopharma GTBP	156 K	$ 0.37	-0.92 %	$ 2.04 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Halozyme Therapeutics HALO	21.5 M	$ 66.86	-1.42 %	$ 8.01 B	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Harmony Biosciences Holdings HRMY	-680 K	$ 28.5	-1.35 %	$ 1.64 B	USA
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
Akebia Therapeutics AKBA	58 K	$ 1.43	2.14 %	$ 368 M	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Allakos ALLK	8 K	-	-	$ 28.6 M	USA
Can-Fite BioPharma Ltd. CANF	227 K	$ 2.91	-0.26 %	$ 4.79 M	Israel
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Aquestive Therapeutics AQST	6.55 M	$ 4.18	2.45 %	$ 447 M	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
Arcutis Biotherapeutics ARQT	443 K	$ 23.96	-1.03 %	$ 3.05 B	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Celldex Therapeutics CLDX	927 K	$ 32.21	-0.09 %	$ 2.14 B	USA
Autolus Therapeutics plc AUTL	36.7 M	$ 1.49	-0.34 %	$ 397 M	Britain
Incyte Corporation INCY	25.1 M	$ 94.65	-1.48 %	$ 18.5 B	USA
Cidara Therapeutics CDTX	5.81 M	-	-	$ 1.41 B	USA
Innate Pharma S.A. IPHA	440 K	$ 1.48	4.61 %	$ 235 M	France
Aytu BioScience AYTU	-512 K	$ 2.57	0.78 %	$ 16.1 M	USA
Inventiva S.A. IVA	12.2 M	$ 5.15	-2.09 %	$ 138 M	France
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA